meibomask®

meibomask® is Espansione Group's dedicated clinical photobiomodulation device, designed for effective management of anterior segment conditions — above all Dry Eye Disease (DED) induced by Meibomian Gland Dysfunction (MGD).

Key Features

Complete & Direct Treatment

meibomask® covers both lower and upper eyelids simultaneously, ensuring full therapeutic coverage and maximum efficacy per session.

Personalised Protocols

meibomask® integrates with me-check® screening data. Based on the severity of Meibomian gland loss detected, the device automatically adjusts the energy output and treatment duration for each individual patient.

Quick & Easy

• Treatment duration: 15 minutes
• Patients report immediate relief following therapy
• Minimal operator training required; no setup time

Non-Invasive

Near-infrared LM™ LLLT light is emitted at medically certified wavelengths, generating endogenous heating by stimulating cellular ATP production — no ablation, no discomfort.

Treatable Conditions

• Dry Eye Disease (DED) from MGD
• Chalazion
• Blepharitis
• Other anterior segment ocular surface conditions

Technology

meibomask® leverages the full LM™ LLLT photobiomodulation platform. The near-infrared emission increases and stabilises the tear lipid layer, directly addressing the primary cause of evaporative dry eye.

All treatments are CE certified (MDR) for clinical use.